Health X Platform flags Genu Path Labs going-concern uncertainty

Health X Platform Limited disclosed on November 14, 2026 that Genu Path Labs Limited had completely eroded net worth as at September 30, 2026, and its auditors had communicated a material uncertainty relating to going concern. Health X Platform’s consolidated auditor retained an unmodified limited-review conclusion while highlighting the subsidiary-level matter.

What did Health X Platform’s auditors say about Genu Path Labs?

Health X Platform’s auditors said Genu Path Labs, a step-down subsidiary, had completely eroded net worth at September 30, 2026 and that its auditors had communicated a material uncertainty relating to going concern. JKVS & Co included the matter in an emphasis-of-matter paragraph in its review report on the unaudited consolidated results for the quarter and half year ended September 30, 2026.

Genu Path Labs’ financial statements were prepared on a going-concern basis, according to the review report’s reference to Note 6 of the consolidated statement. JKVS & Co said its conclusion was not modified in respect of this matter. A limited review provides moderate assurance and is narrower in scope than an audit, as the report states.

The supplied filing does not disclose separate revenue, loss, assets, liabilities, borrowings, cash balance or the amount of negative net worth for Genu Path Labs. It also does not state that the subsidiary has ceased operations, entered insolvency proceedings or received a new funding commitment. The disclosed position is therefore a going-concern uncertainty at September 30, 2026 rather than a quantified subsidiary financial profile.

How were subsidiary financial figures reviewed for September 2026?

Health X Platform’s review report separates financial information reviewed by other auditors from information for seven step-down subsidiaries that was furnished by management and not reviewed by their auditors. The report does not identify which individual entities are included in either numerical pool, so neither set of figures can be assigned specifically to Genu Path Labs.

The five entities covered by other auditors reported a net loss of Rs 4.76 crore for the quarter ended September 30, 2026, followed by net profit of Rs 8.98 lakh for the April 1 to September 30, 2026 period. Their total comprehensive loss was Rs 4.69 crore for the quarter, compared with total comprehensive income of Rs 2.73 lakh for the six-month period, and net cash inflow was Rs 1.62 crore in the half year.

The seven unreviewed step-down subsidiaries reported net losses of Rs 33.92 lakh in the September 2026 quarter and Rs 43.61 lakh in the half year. Their total comprehensive losses were Rs 33.60 lakh and Rs 42.97 lakh respectively, while their six-month net cash outflow was Rs 21.75 lakh. Management told the auditor that this unreviewed interim financial information was not material to the group.

What do Health X Platform’s healthcare network results show?

Health X Platform’s healthcare network reported Rs 31.40 crore in segment revenue for the half year ended September 30, 2026, against no reported revenue in the corresponding half year ended September 30, 2025. Its loss before finance costs and tax nevertheless widened to Rs 28.74 crore from Rs 28.54 crore a year earlier.

The September 2026 quarter produced healthcare-network revenue of Rs 28.84 crore and a segment loss before finance costs and tax of Rs 13.87 crore. In the preceding June 2026 quarter, revenue was Rs 28.51 crore and the loss was Rs 14.87 crore. Thus, quarterly revenue increased by Rs 32.93 lakh while the reported segment loss narrowed by Rs 99.88 lakh.

Healthcare-network assets were Rs 768.10 crore at September 30, 2026, down from Rs 844.69 crore at September 30, 2025. Segment liabilities rose to Rs 183.74 crore from Rs 124.06 crore over the same period. These are segment-level figures and do not establish the assets, liabilities or performance of Genu Path Labs alone.

Financial services, another reported segment, recorded half-year revenue of Rs 898.00 crore, compared with Rs 586.48 crore in the prior-year period. Its result before finance costs and tax changed to a loss of Rs 16.44 lakh from a profit of Rs 12.14 crore. The comparison shows that the consolidated financial statements cover activities beyond the healthcare network and its diagnostics-related subsidiaries.

What is the status of the Sastasundar Healthbuddy scheme?

Health X Platform’s board approved a composite scheme of arrangement and amalgamation on June 10, 2026 involving Health X Platform, Innogrow Technologies Limited and Sastasundar Healthbuddy Limited. The scheme’s appointed date is April 1, 2026, but it remained subject to requisite approvals when the September 30, 2026 results were issued.

No accounting effect from the proposed scheme had been recorded in the half-year financial results because approvals were pending. Health X Platform reported Rs 14.75 lakh of scheme-related expenses in the quarter ended June 30, 2026 under other expenses. The supplied filing does not disclose a specific loan, guarantee, equity infusion or other financial-support arrangement by Sastasundar Healthbuddy for Genu Path Labs.

Conclusion

Genu Path Labs’ completely eroded net worth is the central disclosure in Health X Platform’s September 30, 2026 consolidated review. The unmodified review conclusion does not remove the emphasis-of-matter disclosure: the subsidiary’s accounts remain prepared on a going-concern basis despite the material uncertainty communicated by its auditors.

The next disclosed event to watch is progress on approvals for the June 10, 2026 composite scheme, for which accounting has not yet been recorded despite an April 1, 2026 appointed date. Future disclosures may also provide the details absent from this filing, including any Genu Path Labs turnaround actions, funding arrangements or updated going-concern assessment.